04:03 AM EDT, 09/08/2025 (MT Newswires) -- Alkermes ( ALKS ) said Sunday that a phase 2 study of its investigational drug alixorexton in patients with type 1 narcolepsy showed "clinically meaningful" and "statistically significant" improvements in wakefulness, cognition and fatigue that were sustained over a six-week treatment period.

The 92-patient study met its primary endpoint of improvements in mean sleep latency at six weeks across all dosages and showed "robust and clinically meaningful improvements" on the secondary endpoint of sleepiness.

It also showed "numerical and clinically meaningful improvements" across all doses compared to placebo in reducing cataplexy.